ArticleAmerican journal of respiratory and critical care medicine2018
Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04232618 (Field Evaluation of a Point-of-care Triage Test for Active Tuberculosis), which is not on this map. Cited by 159 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 5 pooled it
19.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Field Evaluation of a Point-of-care Triage Test for Active Tuberculosis
Who cites it
159 citing papers in PubMed, 5 syntheses or guidelines pooled it, 263 citations in OpenAlex.
- Biomarker tests of progression from tuberculosis infection to disease: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis.The Lancet. Respiratory medicine · 2020Pooled it
- Pooled it
- Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures.PLoS medicine · 2019Pooled it
- Transcriptional signatures of human peripheral blood mononuclear cells can identify the risk of tuberculosis progression from latent infection among individuals with silicosis.Emerging microbes & infections · 2021Trial
- Whole blood mRNA expression-based targets to discriminate active tuberculosis from latent infection and other pulmonary diseases.Scientific reports · 2020Trial
- Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis.Frontiers in immunology · 2019Trial
- The host transcriptional response to real-world cryptococcosis in the setting of advanced HIV disease defines dysregulated immune responses that underlie increased vulnerability to infection.The Journal of infectious diseases · 2026Article
- Blood transcriptomic signatures predict poor outcomes in drug-susceptible pulmonary tuberculosis in Brazil.American journal of respiratory and critical care medicine · 2026Article
- Single-Cell Immune Profiling Suggests Non-Classical Monocyte Is Associated Immunodepression in Tuberculosis Treatment Non-Responders.Journal of cellular and molecular medicine · 2026Article
- TRIM21 blocks DDX3X-driven stress granule formation during Mycobacterium tuberculosis infection via a non-canonical E3 ligase mechanism.PLoS pathogens · 2026Article
- Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis.Nature communications · 2026Article
- Monocyte-Amplified Transcriptional Signatures of Human Diseases.bioRxiv : the preprint server for biology · 2026Article
- Integration of transcriptome and mendelian randomization elucidates the protective role of aspirin in pulmonary tuberculosis development.Functional & integrative genomics · 2026Article
- RISK6 as a Translational Host Transcriptomic Signature for Tuberculosis Diagnosis, Treatment Monitoring, and Risk Stratification.Pathogens (Basel, Switzerland) · 2026Review
- Plasma protein biomarkers predictive of progression to active tuberculosis among close contacts of patients with tuberculosis.iScience · 2026Article
- Host response biomarkers of tuberculosis recurrence and treatment failure.Communications medicine · 2026Article
- Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods.Diseases (Basel, Switzerland) · 2026Review
- Latent tuberculosis infection in high TB disease burden countries dysregulates cellular and immunological profiles which is further enhanced with uncontrolled hyperglycemia.Scientific reports · 2026Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors at 11 institutions in 9 countries.
Sara SulimanSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.ORCID http://orcid.org/0000-0002-5154-576X
Ethan G ThompsonThe Center for Infectious Disease Research, Seattle, Washington.
Jayne SutherlandVaccines and Immunity, Medical Research Council Unit, Fajara, the Gambia.
January WeinerMax Planck Institute for Infection Biology, Berlin, Germany.
Martin O C OtaVaccines and Immunity, Medical Research Council Unit, Fajara, the Gambia.
Smitha ShankarThe Center for Infectious Disease Research, Seattle, Washington.
Adam Penn-NicholsonSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Bonnie ThielCase Western Reserve University, Cleveland, Ohio.
Mzwandile ErasmusSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Jeroen MaertzdorfMax Planck Institute for Infection Biology, Berlin, Germany.
Fergal J DuffyThe Center for Infectious Disease Research, Seattle, Washington.
Philip C HillCentre for International Health, School of Medicine, University of Otago, Dunedin, New Zealand.
E Jane HughesSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Kim StanleyDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, and.
Katrina DowningSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Michelle L FisherSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Joe ValvoThe Center for Infectious Disease Research, Seattle, Washington.
Shreemanta K ParidaMax Planck Institute for Infection Biology, Berlin, Germany.
Gian van der SpuyDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, and.
Gerard TrompDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, and.
Ifedayo M O AdetifaVaccines and Immunity, Medical Research Council Unit, Fajara, the Gambia.
Simon DonkorVaccines and Immunity, Medical Research Council Unit, Fajara, the Gambia.
Rawleigh HoweImmunology Unit, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Harriet Mayanja-KizzaDepartment of Medicine, and.
W Henry BoomCase Western Reserve University, Cleveland, Ohio.
Hazel M DockrellDepartment of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom; and.
Tom H M OttenhoffDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Alan AderemThe Center for Infectious Disease Research, Seattle, Washington.
Willem A HanekomSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and.
Stefan H E KaufmannMax Planck Institute for Infection Biology, Berlin, Germany.
Daniel E ZakThe Center for Infectious Disease Research, Seattle, Washington.
Gerhard WalzlDepartment of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research, and.
GC6-74 cohort study team, The ACS cohort study team
University of Cape Town · ZACenter for Infectious Disease Research · USMax Planck Institute for Infection Biology · DEMRC Unit the Gambia · GMSouth African Medical Research Council · ZACase Western Reserve University · USArmauer Hansen Research Institute · ETLeiden University Medical Center · NLLondon School of Hygiene & Tropical Medicine · GBMakerere University · UGUniversity of Otago · NZ
Funding
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1MTuberculosis Prevention Research Unit /TBRU/-266095383N01AI095383 · NIAID · CASE WESTERN RESERVE UNIVERSITY · 2000 to 2005
$5.6MHost determinants of protection against tuberculosis in adolescentsR01AI087915 · NIAID · UNIVERSITY OF CAPE TOWN · PI SCRIBA, THOMAS JENS · 2011 to 2015
$3.3MBiology and Biosignatures of Anti-Tuberculosis Treatment ResponseU01AI115619 · NIAID · COLORADO STATE UNIVERSITY · PI BELISLE, JOHN T · 2015 to 2019
$3.1MFIC NIH HHS D43 TW000231Medical Research Council MC_U190071468Medical Research Council MC_UP_A900_1122NIAID NIH HHS N01 AI070022NIAID NIH HHS N01 AI095383NIAID NIH HHS R01 AI087915NIAID NIH HHS U01 AI115619
Abstract
PubMed holds no abstract for this paper.
Indexed as
biomarkersgene expressiontuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04232618ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.